Multiple GLP-1 agonists are approved for treatment of type 2 diabetes and recently high dose liraglutide was also approved for treatment of obesity, as it promotes sustained weight loss via effects on satiety and appetite [5, 39]. Here, GCG is linked to obesity disorder.